In this thesis, we provide evidence that suggests that the increased bleeding risk outweighs the efficacy (preventing stent thrombosis, myocardial infarction (MI), stroke and thromboembolism) benefit of triple therapy in these patients and we present a possible new strategy of VKA and a P2Y12 inhibitor alone. This evidence concerns the gene P2RY12 and Stroke.